European expansion CE Mark approval for CT:VQ enabling commercial launch across the European Union along with financing to support growth indicates readiness to pursue European hospital networks and imaging centers as new customers.

US market push Significant US funding to accelerate adoption of CT:VQ and scale hospital deployments suggests aggressive sales opportunities with major U.S. health systems, academic centers, and early adopters.

Clinical adoption Active discussions around CT:VQ use in patient selection for lung volume reduction surgery highlight a pathway to partner with thoracic surgeons, pulmonologists, and multidisciplinary teams for contextually valuable imaging tools.

Product leadership Positioning as a software-based lung-imaging leader with quantitative, high-resolution functional imaging creates cross-selling potential into radiology software platforms, AI-driven analytics partnerships, and life sciences collaborations.

Strategic partnerships Expanding distribution agreements and collaborations with hospitals, research institutions, and potential M&A interest signal opportunities to align with system integrators and regional distributors to accelerate broad uptake of CT:VQ.